Pharma BD Deal Intelligence
Sanofi paid ~$550M for Acambis in 2008, then sold the crown-jewel ACAM2000 smallpox vaccine business to Emergent BioSolutions in 2017 for up to $125M — a fraction of the original price, with a 2010 SEC filing calling the CDC stockpile contract "not significant" to Sanofi's financials.
Full analysis, sources & comparables →Sanofi's $548M takeover of Acambis at a 64% premium was framed as a logical extension of an existing partnership, anchored by the $425M 10-year US smallpox…
C&EN framed Sanofi's Acambis purchase as evidence of the growing strategic value of the vaccines market for big pharma facing patent cliffs.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
GBP 276M; ACAM2000 smallpox; Japanese encephalitis, West Nile, Dengue programs; closed Sep 25 2008
Sanofi paid ~$550M for Acambis in 2008, then sold the crown-jewel ACAM2000 smallpox vaccine business to Emergent BioSolutions in 2017 for up to $125M — a fraction of the original price, with a 2010 SEC filing calling the CDC stockpile contract "not significant" to Sanofi's financials.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi-Aventis / Acambis plc (this deal) | 2008 | $548M | 36 |
| Sanofi-Aventis / Symbion Consumer (Primary Health Care) | 2008 | $544M | 71 |
| Sanofi-Aventis / Merial Limited (Merck's 50% interest) | 2009 | $4.0B | 65 |
| Sanofi-Aventis / Shantha Biotechnics Limited | 2009 | $784M | 34 |
| Sanofi-Aventis / Fovea Pharmaceuticals SA | 2009 | $541M | 23 |
| Sanofi-Aventis / BiPar Sciences, Inc. | 2009 | $500M | 8 |
| Sanofi-Aventis / ImmunoGen Inc. | 2005 | $18M | — |
← Browse all deals · How we score deals
More: 2008 deals · Sanofi-Aventis deals